---
id: 248
title: Cryptococcus neoformans
category: organisms
subcategory: fungi
tags: [Cryptococcus, cryptococcal-meningitis, HIV, amphotericin-B, flucytosine, India-ink]
difficulty: high
---

## Question

What are key clinical syndromes and treatment considerations for *Cryptococcus*? Use **"Meningitis: Amphotericin B + Flucytosine (Induction) → Fluconazole (Consolidation/Maintenance), HIV CD4 <100"** framework.

## Answer

### **Species:**

***C. neoformans*** (worldwide, pigeon droppings, HIV)
***C. gattii*** (Pacific Northwest, Australia, immunocompetent)

### **Key Clinical Syndromes:**

**Cryptococcal Meningitis:**
- **Most common manifestation** (HIV CD4 <100)
- **Subacute onset:** Headache, fever, altered mental status
- **↑Intracranial pressure** (can be severe, vision loss, herniation)
- **High mortality** (10-30% despite treatment in HIV; higher in non-HIV)

**Pulmonary Cryptococcosis:**
- **Asymptomatic nodules** (immunocompetent) → observation
- **Pneumonia** (immunocompromised) → treat
- **Can disseminate** to CNS

**Disseminated Cryptococcosis:**
- **CNS, lungs, skin, bone, prostate**
- **Cutaneous lesions** (umbilicated, molluscum-like)

**Cryptococcemia:**
- **Bloodstream infection** (often with meningitis)

### **Diagnosis:**

**CSF Analysis (Meningitis):**
- **Opening pressure:** Often **elevated** (>25 cm H₂O, can be >50)
- **WBC:** 20-200 (lymphocytic predominance)
- **Protein:** ↑ (50-200 mg/dL)
- **Glucose:** ↓ or normal
- **India ink stain:** 50-80% positive (encapsulated yeast)

**Cryptococcal Antigen (CrAg):**
- **CSF CrAg:** Highly sensitive (>95%), specific
- **Serum CrAg:** Positive in CNS disease (screen for dissemination)
- **Titer >1:1024** suggests high fungal burden

**Culture:**
- **CSF, blood culture** (grows in 3-7 days)
- **Gold standard**

**Screening (HIV CD4 <100):**
- **Serum CrAg** (screen asymptomatic patients)
- **If positive → LP** (r/o CNS disease)

### **Treatment:**

**Cryptococcal Meningitis (HIV-Positive):**

**Induction (2 Weeks):**
- **Liposomal amphotericin B 3-4 mg/kg IV daily**
- **+ Flucytosine 100 mg/kg/day PO divided QID** (25 mg/kg QID)
- **Goal:** Sterilize CSF (repeat LP at 2 weeks, culture should be negative)

**Consolidation (8 Weeks):**
- **Fluconazole 400mg PO daily × 8 weeks**

**Maintenance (≥1 Year):**
- **Fluconazole 200mg PO daily**
- **Continue until:** CD4 >200 × 6 months on ART + undetectable HIV RNA
- **Lifelong** if cannot achieve immune reconstitution

**ART Timing:**
- **Delay ART 4-6 weeks** after starting antifungals (reduce IRIS risk)

**Cryptococcal Meningitis (HIV-Negative):**
- **Liposomal amphotericin B 3-4 mg/kg IV daily + flucytosine 100 mg/kg/day × 4-6 weeks** (longer induction than HIV+)
- **Then fluconazole 400-800mg daily × 8 weeks** (consolidation)
- **Then fluconazole 200mg daily × 6-12 months** (maintenance)

**Alternative Induction (If Flucytosine Unavailable):**
- **Liposomal amphotericin B 3-4 mg/kg IV daily + fluconazole 800mg PO daily × 2 weeks**
- **Less effective** than amphotericin + flucytosine

**Pulmonary Cryptococcosis:**

**Asymptomatic (Immunocompetent):**
- **Observation** (if serum CrAg negative, no CNS symptoms)
- **Fluconazole 400mg daily × 6-12 months** (if symptomatic or CrAg positive)

**Symptomatic/Immunocompromised:**
- **LP mandatory** (r/o CNS disease)
- **If CNS disease:** Treat as meningitis
- **If isolated pulmonary:** Fluconazole 400mg daily × 6-12 months

**Increased Intracranial Pressure (ICP) Management:**

**Critical Complication:**
- **Vision loss, herniation, death** if untreated

**Therapeutic LP:**
- **Daily LPs** until opening pressure <25 cm H₂O
- **Remove 10-30 mL CSF** to lower pressure by 50%
- **Continue until normalized**

**VP Shunt:**
- **If refractory** to serial LPs (consider if failing repeated LPs)

**Avoid:**
- **Acetazolamide, mannitol, steroids** (NOT effective, may harm)

### **Monitoring:**

**Induction Phase:**
- **Repeat LP at 2 weeks** (culture should be negative)
- **If positive at 2 weeks:** Extended induction (poor prognosis)
- **Monitor flucytosine levels** (trough 25-100 mcg/mL, avoid toxicity)
- **Monitor Cr, K, Mg** (amphotericin B nephrotoxicity)
- **CBC** (flucytosine myelosuppression)

**Follow-Up:**
- **Opening pressure** (serial LPs if elevated)
- **CD4 count** (if HIV, guide duration of maintenance)

### **Immune Reconstitution Inflammatory Syndrome (IRIS):**

**Paradoxical Worsening:**
- **2-8 weeks** after starting ART
- **Worsening meningeal symptoms** despite sterile CSF
- **Inflammatory response** (not active infection)

**Management:**
- **Continue antifungals + ART**
- **NSAIDs, corticosteroids** (if severe)
- **Manage ↑ICP** (therapeutic LPs)

### **Special Populations:**

**HIV CD4 <100:**
- **Screen with serum CrAg** (if positive → LP)
- **Preemptive fluconazole 800mg × 2 weeks → 400mg × 8 weeks** (if CrAg+ but LP negative)

**Transplant Recipients:**
- **Immunosuppression** (calcineurin inhibitors)
- **Treat as HIV-negative** (longer induction)

**Pregnancy:**
- **Amphotericin B safe**
- **Flucytosine contraindicated** (teratogenic) - use amphotericin B alone or add fluconazole

### **Prognosis:**

**Mortality:**
- **HIV+ (treated):** 10-30%
- **HIV- (treated):** 20-40%
- **Untreated:** >90%

**Predictors of Poor Outcome:**
- **Altered mental status**
- **High fungal burden** (CSF CrAg >1:1024)
- **↑ICP** (uncontrolled)
- **Failure to sterilize CSF** by 2 weeks

## Key Points

### **Induction: Amphotericin B + Flucytosine × 2 Weeks:**
- **Liposomal amphotericin B 3-4 mg/kg IV daily**
- **+ Flucytosine 100 mg/kg/day PO divided QID**

### **Consolidation: Fluconazole 400mg × 8 Weeks:**
- **After negative CSF culture at 2 weeks**

### **Maintenance: Fluconazole 200mg Daily ≥1 Year:**
- **Until CD4 >200 × 6 months** (if HIV)

### **Manage ↑ICP Aggressively:**
- **Daily therapeutic LPs** (until pressure <25 cm H₂O)
- **Critical for preventing vision loss, herniation**

### **Delay ART 4-6 Weeks:**
- **Reduce IRIS risk** (HIV patients)

### **Clinical Pearls:**
- **Induction:** Amphotericin B 3-4 mg/kg + flucytosine 100 mg/kg/day × 2 weeks
- **Consolidation:** Fluconazole 400mg × 8 weeks
- **Maintenance:** Fluconazole 200mg daily ≥1 year (until CD4 >200 × 6 months if HIV)
- **↑ICP:** Daily LPs (lower by 50%, until <25 cm H₂O) - critical
- **Delay ART** 4-6 weeks (reduce IRIS)
- **Repeat LP at 2 weeks** (culture should be negative)

## Sources

- [IDSA: Cryptococcal Disease Guidelines 2024]
- [WHO: Cryptococcal Meningitis Management 2024]

## Media

N/A
